Humacyte, Inc.
HUMA
$1.39
$0.010.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 495.00K | 467.00K | 753.00K | 301.00K | 517.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 495.00K | 467.00K | 753.00K | 301.00K | 517.00K |
| Cost of Revenue | 20.90M | 23.69M | 17.53M | 22.22M | 15.57M |
| Gross Profit | -20.41M | -23.22M | -16.78M | -21.92M | -15.05M |
| SG&A Expenses | 7.83M | 7.62M | 7.61M | 7.81M | 8.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.73M | 31.30M | 25.14M | 30.03M | 23.70M |
| Operating Income | -28.24M | -30.84M | -24.39M | -29.73M | -23.18M |
| Income Before Tax | -17.62M | -24.80M | -17.51M | -37.66M | 39.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.62M | -24.80M | -17.51M | -37.66M | 39.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.62M | -24.80M | -17.51M | -37.66M | 39.14M |
| EBIT | -28.24M | -30.84M | -24.39M | -29.73M | -23.18M |
| EBITDA | -26.45M | -29.05M | -22.53M | -27.87M | -21.35M |
| EPS Basic | -0.09 | -0.13 | -0.11 | -0.24 | 0.28 |
| Normalized Basic EPS | -0.07 | -0.04 | -0.09 | -0.13 | -0.05 |
| EPS Diluted | -0.09 | -0.13 | -0.11 | -0.24 | 0.28 |
| Normalized Diluted EPS | -0.07 | -0.04 | -0.09 | -0.13 | -0.05 |
| Average Basic Shares Outstanding | 197.85M | 186.79M | 158.31M | 155.44M | 131.50M |
| Average Diluted Shares Outstanding | 197.85M | 186.79M | 158.31M | 155.44M | 131.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |